Information about the product

Birdshot retinochoroidopathy (BSRC) is a rare, chronic, bilateral, posterior uveitis characterized by distinctive, multiple, hypopigmented choroidal and retinal lesions. The pathogenesis is unknown, but HLA-A29 positivity appears to confer predisposition, and retinal autoimmunity seems to play a role.

The relative risk of BSRC among HLA-A29-positive individuals has been estimated to be 50 to 224, and most investigators recognize the presence of the HLA-A29 allele as a necessary criterion for BSRC diagnosis for research purposes. HLA-A29 is present in as many as 7% of Caucasians, and is subdivi¬ded into more than 20 subtypes.

Intended use

Genvinset® HLA A29 is a semi-automated in vitro diagnostic kit for the qualitative detection of the HLA-A*29 group of alleles in genomic DNA extracted from whole blood, associated with Birdshot retinochoroidopathy predisposition, by real-time PCR using TaqMan® probes technology.

Patients who can benefit from this determination are those referred by a specialist. The results of this test should not be the only ones on which the therapeutic decision is based and should be used as an aid in the diagnosis together with results of other markers of the disease.

The intended user of the kit is technical personnel trained to carry out the protocol and the interpretation of results described in the instructions for use.

Workflow

workflow genvinset 2
Genvinset® HLA A29 5

Results

Genvinset HLA A29 Negative sample
Genvinset HLA A29 Positive sample
leyenda 8

Limitations

  • Mutations or polymorphisms at annealing primer/probe sites are possible and may result in the lack of allele definition. Other technologies could be necessary to resolve the typing.
  • Data and result interpretation should be revised by qualified personnel.
  • This product is an auxiliary tool for the diagnosis of patients with suspected birdshot retinochoroidopathy. Use these results in conjunction with clinical data and results of other tests performed on the patient.

Area:

HLA associated diseases, HLA associated diseases, Immunology, Molecular Genetics, Targeted study of specific pathologies

Documents:

Consult our experts

Google reCaptcha: Invalid site key.

Related products

Devyser LynchFAP

Devyser LynchFAP is a targeted NGS solution for the analysis of germline variants associated with hereditary colorectal cancer syndromes. The assay enables the detection of SNVs, indels, and CNVs in genes related to Lynch syndrome, familial adenomatous polyposis (FAP), and MUTYH-associated polyposis (MAP), also incorporating a specific LR-PCR for the correct localization of variants in…
Devyser
Next Generation Sequencing (NGS)

Devyser HBOC NGS

Devyser HBOC NGS is a fast and robust NGS solution aimed at the detection of germline variants in 12 genes associated with an increased risk of hereditary breast and ovarian cancer: ATM, BARD1, BRIP1, CDH1, CHEK2, NBN, PALB2, PTEN, RAD51C, RAD51D, STK11, TP53. It offers comprehensive and uniform coverage of all coding exons and exon/intron…
Devyser
Next Generation Sequencing (NGS)

Devyser BRCA NGS

Devyser BRCA NGS is a fast and robust NGS solution designed for the detection of genetic variants in the BRCA1 and BRCA2 genes. It offers comprehensive and uniform coverage of all coding exons and exon/intron junctions of both genes. In addition, it includes the detection of single nucleotide variants (SNVs), insertions/deletions (Indels), and copy number…
Devyser
Next Generation Sequencing (NGS)

Devyser BRCA PALB2 NGS

Devyser BRCA PALB2 NGS is a fast and robust NGS solution designed for the detection of genetic variants in the BRCA1, BRCA2, and PALB2 genes. It offers comprehensive and uniform coverage of all coding exons and exon/intron junctions of both genes. In addition, it includes the detection of single nucleotide variants (SNVs), insertions/deletions (Indels), and…
Devyser
Next Generation Sequencing (NGS)